Sofie S. Schmøkel

Sofie S. Schmøkel

Auto-generated profile, based on publicly available information

Sofie S. Schmøkel

Department of Clinical Medicine, Aarhus University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SSSofie S. Schmøkel
Sofie S. Schmøkel
INIver K. Nordentoft
Iver K. Nordentoft
SLSia V. Lindskrog
Sia V. Lindskrog
PLPhilippe Lamy
Philippe Lamy
MKMichael Knudsen
Michael Knudsen
LDLars Dyrskjøt
Lars Dyrskjøt
This paper provides a laboratory workflow for single-nucleus RNA-sequencing (snRNA-seq) including a protocol for gentle nuclei isolation from fresh frozen tumor biopsies, making it possible to analyze biobanked material. To develop this protocol, we used non-frozen and frozen human bladder tumors and cell lines. We tested different lysis buffers (IgePal and Nuclei EZ) and incubation times in combination with different approaches for tissue and cell dissection; sectioning, semi-automated dissociation, manual dissociation with pestles, and semi-automated dissociation combined with manual dissociation with pestles. Our results showed a combination of IgePal lysis buffer, tissue dissection by sectioning and short incubation time was the best conditions for gentle nuclei isolation applicable for snRNA-seq, and we found limited confounding transcriptomic changes based on the isolation procedure. This protocol makes it possible to analyze biobanked material from patients with well described clinical and histopathological information and known clinical outcomes with snRNA-seq.

27 October 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
SLSia V. Lindskrog
Sia V. Lindskrog
SSSofie S. Schmøkel
Sofie S. Schmøkel
INIver Nordentoft
Iver Nordentoft
PLPhilippe Lamy
Philippe Lamy
MKMichael Knudsen
Michael Knudsen
LDLars Dyrskjøt
Lars Dyrskjøt
Current transcriptomic classification systems for bladder cancer do not consider the level of intra-tumor subtype heterogeneity. Here we present an investigation of the extent and possible clinical impact of intra-tumor heterogeneity across early and more advanced disease stages of bladder cancer. We performed single nucleus RNA-sequencing of 48 bladder tumors and four of these tumors were additionally analyzed using spatial transcriptomics. Total bulk RNA-sequencing and spatial proteomics data were available from the same tumors for comparison, along with detailed clinical follow-up of the patients. We demonstrate that tumors display varying levels of intra-tumor subtype heterogeneity and show that a higher class 2a weight estimated from bulk RNA-sequencing data is associated with worse outcome in patients with molecular high-risk class 2a tumors. Our results indicate that discrete subtype assignments from bulk RNA-sequencing data may lack biological granularity and continuous class scores could improve clinical risk stratification of patients. Highlights Single nucleus RNA-sequencing of tumors from 48 bladder cancer patients. Tumors display varying levels of intra-tumor subtype heterogeneity at single nucleus and bulk tumor level. The level of subtype heterogeneity could be estimated from both single nucleus and bulk RNA-sequencing data with a high concordance between the two. High class 2a weight estimated from bulk RNA-sequencing data is associated with worse outcome in patients with molecular high-risk class 2a tumors.